DiscoverASCO Education
ASCO Education
Claim Ownership

ASCO Education

Author: ASCO Education

Subscribed: 222Played: 6,010
Share

Description

ASCO Education: By the Book delivers in-depth discussions with the editors and authors behind the ASCO Educational Book. Hear about key topics from ASCO meetings education sessions, perspectives on the state of the science, and deep dives into the complex approaches shaping modern oncology practice.
203 Episodes
Reverse
Dr. Kimmie Ng sits down with host Dr. Hope Rugo to discuss the steady rise in early-onset cancer globally, as detailed in the co-authored ASCO Educational Book article, Understanding Contemporary Challenges in the Care of Patients With Early-Onset Cancer: Epidemiologic Trends, Patient Well-Being, Oncofertility, and Cancer Survivorship. LINK TO FULL TRANSCRIPT  
Dr. Christopher Booth joins guest host Dr. Gerald Hsu to discuss his ASCO Educational Book article, "Innovation, Evidence, Compassion, and Hope: Delivering Outcomes That Matter," exploring how modern trial metrics and regulatory pathways frequently prioritize surrogate endpoints over meaningful survival and quality-of-life gains. Together, they discuss actionable strategies for clinicians and policymakers to  re-center cancer care on shared decision-making, patient priorities, and global access. LINK TO FULL TRANSCRIPT
Guest host Dr. Gerald Hsu and Dr. Martin Dreyling discuss the latest clinical data in mantle cell lymphoma, as well as risk stratification methods and the future role of chemo-free regimens and immunotherapy in MCL. LINK TO FULL TRANSCRIPT
Dr. Pedro Barata and Dr. Giuseppe Curigliano discuss the rapid paradigm shift of antibody-drug conjugates into frontline advanced and curative-intent perioperative settings and the clinical challenges of optimal sequencing, target selection, and cross-resistance. LINK TO FULL TRANSCRIPT
Dr. Pedro Barata and Dr. Bridget Keenan discuss the innovative bioengineering allowing clinicians to target historically "immune-cold" tumors, the logistical evolution of bringing bispecific therapies safely into outpatient community clinics, and the complex future of predictive biomarkers and resistance mechanisms. LINK TO FULL TRANSCRIPT
loading
Comments